Please provide your email address to receive an email when new articles are posted on . Lyu and colleagues analyzed electronic medical records data from 151 adults aged at least 45 years identified as ...

New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen ...

On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; 70 mg/mL injection), referencing Amgen’s PROLIA® and ...

AIHI research finds the recommended treatments are frequently missed or delayed in residential aged care, increasing the risk ...

Please provide your email address to receive an email when new articles are posted on . Bisphosphonate use before denosumab discontinuation was associated with less bone mineral density loss among ...

August 11, 2009 — Denosumab injections are associated with lower fracture rate in postmenopausal women with osteoporosis, according to the results of an international, randomized, double-blind, ...

Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures "The European approval of Prolia is a ...

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the supplemental application for MAIWEIJIAN (Denosumab Injection, R ...

MONTREAL, QUEBEC — Two recent studies — a case series and a secondary analysis of a large phase 3 trial — shed more light on the rare increased risk of vertebral fractures after discontinuing ...